Ibuprofen and Famotidine Tablets Recalled for Foreign Tablet Contamination
Ascend Laboratories is recalling 3,288 bottles of Ibuprofen and Famotidine tablets nationwide because a stray Rasagiline Mesylate tablet was discovered in an unopened bottle during quality control.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves foreign object contamination in a prescription medication bottle. The hazard—a stray tablet of a different medication—poses a risk of harm if a consumer accidentally takes the wrong medication. No injuries have been reported.
Plain-English summary
Ascend Laboratories, LLC is recalling 3,288 bottles of Ibuprofen and Famotidine tablets (800mg/26.6mg) due to the presence of a foreign tablet. The affected bottles are distributed nationwide with lot code 23140190 and expiration date 12/31/2024.
A stray Rasagiline Mesylate 1 mg tablet was discovered in an unopened bottle during quality control. Rasagiline Mesylate is a different medication used for Parkinson's disease. The presence of this foreign tablet could result in a consumer accidentally taking the wrong medication.
This recall was issued by the FDA and is classified as a Class II recall.
The recalled product
- Product
- IBUPROFEN AND FAMOTIDINE (IBUPROFEN AND FAMOTIDINE)
- Brand
- IBUPROFEN AND FAMOTIDINE
- Manufacturer
- Ascend Laboratories, LLC
- Hazard
- foreign-tablet
- product-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- 23140190
- Exp. Date 12/31/2024
UPCs (2)
- 0367877626901
- 0367877626062
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01